HopeAI
HopeAI is dedicated to bringing data-driven insights and statistical innovations to clinical development teams through AI-powered solutions. Their mission is to bring hope to patients through AI by enabling smaller, faster, and more successful clinical trials, and providing reliable, up-to-date clinical evidence to support evidence-based medicine in oncology.
Industries
Nr. of Employees
small (1-50)
Products
Clinical evidence synthesis product
Productized platform capability that delivers curated, standardized clinical evidence and supports natural-language queries for clinical teams.
Synthetic IPD product
Product offering that provides synthetic individual-level datasets derived from trial results for simulation and analysis.
Clinical evidence synthesis product
Productized platform capability that delivers curated, standardized clinical evidence and supports natural-language queries for clinical teams.
Synthetic IPD product
Product offering that provides synthetic individual-level datasets derived from trial results for simulation and analysis.
Services
Platform service that aggregates, curates, and standardizes clinical evidence across publications and trials and provides natural-language access to synthesized results.
Service to produce synthetic patient-level datasets derived from published trial results to enable simulation, subgroup analysis, and trial planning while reducing privacy risk.
Design consultancy offering covariate-adjusted response-adaptive randomization strategies and statistical design services for precision-medicine and other clinical trials.
Clinical decision-support service allowing oncologists to query treatment regimens and underlying trial evidence via natural-language interface, combined with expert-curated validation.
Platform service that aggregates, curates, and standardizes clinical evidence across publications and trials and provides natural-language access to synthesized results.
Service to produce synthetic patient-level datasets derived from published trial results to enable simulation, subgroup analysis, and trial planning while reducing privacy risk.
Design consultancy offering covariate-adjusted response-adaptive randomization strategies and statistical design services for precision-medicine and other clinical trials.
Clinical decision-support service allowing oncologists to query treatment regimens and underlying trial evidence via natural-language interface, combined with expert-curated validation.
Expertise Areas
- Clinical trial design and adaptive trials
- Synthetic patient-level data generation
- Evidence synthesis and meta-analysis
- Oncology clinical evidence
Key Technologies
- AI-driven evidence synthesis
- Synthetic individual-patient data generation
- Covariate-adjusted response-adaptive randomization
- Adaptive trial statistical modeling
News & Updates
A paper discussing the use of AI-powered clinical evidence to validate the association between MRD negativity and survival endpoints in multiple myeloma, leading to FDA approval of MRD as an endpoint for accelerated approval.
A paper discussing the use of AI-powered clinical evidence to validate the association between MRD negativity and survival endpoints in multiple myeloma, leading to FDA approval of MRD as an endpoint for accelerated approval.